Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yifan Chen
Observed name:
Yi-fan Chen
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Zhongshan Hospital
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Zhongshan Hospital
ORCID:
0000-0002-5069-3672
Observed ORCID:
0000-0002-5069-3672
OpenAlex ID:
A5004894019
Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28)
2024
·
Yifan Chen
, Yizhao Xie
, et al.
·
Therapeutic Advances in Medical Oncology
·
14
18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival
2025
·
Yizhao Xie
, Yifan Chen
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
·
4
Camrelizumab plus nab-paclitaxel and cisplatin as first-line treatment for metastatic triple-negative breast cancer: A prospective, single-arm, open-label phase II trial.
2025
·
Biyun Wang
, Chengcheng Gong
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Effectiveness, safety, and biomarker analysis of sacituzumab govitecan in Chinese metastatic breast cancer: a multicenter real-world study
2026
·
Mu Li
, Die Sang
, et al.
·
Therapeutic Advances in Medical Oncology
·
1
Dilated cardiomyopathy associated with checkpoint inhibitor therapy: a case report
2026
·
Yihui Shen
, Yuchen Xu
, et al.
·
Journal of Cardio-oncology
Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in China
2025
·
Chengcheng Gong
, Ting Li
, et al.
·
Therapeutic Advances in Medical Oncology
Show more works
View as search
Works count:
6
Citation count:
21
H-index:
2
I10-index:
1
Year
Topic
Type